Table 1. Clinical characteristics of the 56 patients in five groups. Data is expressed as mean±s.d.
| Characteristics | BPH (n=6) | LPC (n=20) | HNPC (n=10) | HSPC (n=10) | HRPC (n=10) | P value* |
|---|---|---|---|---|---|---|
| Age (year) | 66.8±3.5 | 68.3±1.9 | 70.1±2.5 | 69.7±1.5 | 68.6±1.7 | 0.136 |
| Height (cm) | 170.0±4.8 | 171.0±3.7 | 168.7±6.5 | 168.9±5.3 | 172.3±6.9 | 0.469 |
| Weight (kg) | 68.7±10.1 | 72.8±6.9 | 66.4±8.8 | 68.4±7.3 | 75.9±12.4 | 0.125 |
| Serum PSA level (ng ml−1) | 6.99±5.42 | 9.27±5.43 | 245.90±202.19 | 12.79±11.68 | 136.32±128.51 | <0.001 |
| Serum testosterone level (ng dl−1) | 4.48±1.45 | 4.63±1.27 | 3.97±1.13 | 0.16±0.11 | 0.20±0.17 | <0.001 |
| Serum alkaline phosphatase (U l−1) | 66.12±42.79 | 79.45±39.50 | 441.20±302.33 | 237.60±165.25 | 300.40±179.63 | <0.001 |
| Tumour Gleason score | ||||||
| ≤7 | — | 16 | 4 | 5 | 2 | — |
| >7 | — | 4 | 6 | 5 | 8 | — |
| Size of prostate (ml) | 55.8±12.8 | 34.5±13.2 | 42.5±15.6 | 41.1±11.1 | 43.7±11.9 | 0.029 |
| number of bone lesions | ||||||
| ≤2 | — | 0 | 4 | 5 | 3 | — |
| 3–5 | — | 0 | 4 | 2 | 4 | — |
| ≥6 | — | 0 | 2 | 3 | 3 | — |
| Lymph node metastasis | ||||||
| Yes | — | 2 | 6 | 7 | 6 | — |
| No | — | 18 | 4 | 3 | 4 | — |
| Ct value of miR-141 | 34.51±1.65 | 33.77±1.87 | 30.27±0.99 | 31.19±1.41 | 30.02±1.07 | <0.001 |
| Ct value of U6 | 22.48±1.26 | 22.73±1.32 | 22.36±1.08 | 22.51±1.17 | 21.94±0.96 | 0.636 |
| Level of miR-141 (2−ΔCt) (×10−4) | 4.79±3.05 | 10.19±3.00 | 50.53±10.12 | 38.59±13.34 | 46.39±9.93 | <0.001 |
Abbreviations: ANOVA, analysis of variance; BPH, benign prostatic hyperplasia; LPC: localized prostate cancer; HNPC, hormone-naive prostate cancer; HRPC, hormone-refractory prostate cancer; HSPC, hormone-sensitive prostate cancer; PSA, prostate-specific antigen.
—: not applicable.
*One-way ANOVA test is used.